Phase 3CompletedAge-related condition
A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis
- Sponsor
- UCB Biopharma SRL (Industry)
- Enrollment
- 327 enrolled
- Conditions
- Osteoporosis
- Interventions
- Romosozumab; Placebo
- Ages
- adults, older adults
- Registry
- NCT05067335
Full record on ClinicalTrials.gov
From the registry
The purpose of the study is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on the percent changes in bone mineral density (BMD) at the lumbar spine, at the total hip and femoral neck in postmenopausal Chinese women with osteoporosis.
Primary outcomes
- Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine to the End of Double-Blind Period
- Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period
- Percentage of Participants With Treatment-emergent Adverse Events for Romosozumab During Overall Period
History
Last registry update
Results first posted
Primary completion
Started
Registered